Targeting adaptor protein SLP76 of RAGE as a therapeutic approach for lethal sepsis

[1]  Niranjan Kissoon,et al.  Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study , 2020, The Lancet.

[2]  Vijay Kumar,et al.  Advanced Glycation End Products (AGEs) May Be a Striking Link Between Modern Diet and Health , 2019, Biomolecules.

[3]  M. Kuchibhatla,et al.  Damage- and pathogen-associated molecular patterns play differential roles in late mortality after critical illness. , 2019, JCI insight.

[4]  Yong Jiang,et al.  Exosomes Derived From Septic Mouse Serum Modulate Immune Responses via Exosome-Associated Cytokines , 2019, Front. Immunol..

[5]  Hai-hua Luo,et al.  Axin-1 binds to Caveolin-1 to regulate the LPS-induced inflammatory response in AT-I cells. , 2019, Biochemical and biophysical research communications.

[6]  Thomas L. Williams,et al.  Cell-penetrating peptide sequence and modification dependent uptake and subcellular distribution of green florescent protein in different cell lines , 2019, Scientific Reports.

[7]  M. Seminario,et al.  ADAP is an upstream regulator that precedes SLP-76 at sites of TCR engagement and stabilizes signaling microclusters , 2018, Journal of Cell Science.

[8]  F. Tacke,et al.  High mobility group box 1 as a biomarker in critically ill patients , 2018, Journal of clinical laboratory analysis.

[9]  M. Lippman,et al.  Targeting RAGE Signaling in Inflammatory Disease. , 2018, Annual review of medicine.

[10]  Y. Liao,et al.  The impact of RAGE inhibition in animal models of bacterial sepsis: a systematic review and meta-analysis , 2017, The Journal of international medical research.

[11]  M. Chapman,et al.  Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes , 2017, Scientific Reports.

[12]  S. Lemeshow,et al.  Time to Treatment and Mortality during Mandated Emergency Care for Sepsis , 2017, The New England journal of medicine.

[13]  A. Gee,et al.  Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective , 2017, Journal of medicinal chemistry.

[14]  Zekai Halici,et al.  Sepsis and Septic Shock: Current Treatment Strategies and New Approaches. , 2017, The Eurasian journal of medicine.

[15]  A. Schmidt,et al.  Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice , 2016, Front. Cell. Neurosci..

[16]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[17]  S. Rivella,et al.  HMGB1 Mediates Anemia of Inflammation in Murine Sepsis Survivors , 2015, Molecular medicine.

[18]  Y. Vodovotz,et al.  Injury‐induced MRP8/MRP14 stimulates IP‐10/CXCL10 in monocytes/macrophages , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  M. Fink,et al.  Strategies to improve drug development for sepsis , 2014, Nature Reviews Drug Discovery.

[20]  S. Li,et al.  Macrophage endocytosis of high-mobility group box 1 triggers pyroptosis , 2014, Cell Death and Differentiation.

[21]  Denis Thieffry,et al.  Proteomic Analysis of the SH2 Domain-containing Leukocyte Protein of 76 kDa (SLP76) Interactome in Resting and Activated Primary Mast Cells , 2014, Molecular & Cellular Proteomics.

[22]  S. Phipps,et al.  RAGE and TLRs: relatives, friends or neighbours? , 2013, Molecular immunology.

[23]  D. Angus,et al.  Epidemiology of severe sepsis , 2013, Virulence.

[24]  N. Nordin,et al.  Receptor for Advanced Glycation End Products and Its Involvement in Inflammatory Diseases , 2013, International journal of inflammation.

[25]  T. van der Poll,et al.  Severe sepsis and septic shock. , 2013, The New England journal of medicine.

[26]  M. Andrades,et al.  Plasma glycation levels are associated with severity in sepsis , 2012, European journal of clinical investigation.

[27]  A. Zarbock,et al.  Crucial role of SLP-76 and ADAP for neutrophil recruitment in mouse kidney ischemia-reperfusion injury , 2012, The Journal of experimental medicine.

[28]  A. Schmidt,et al.  Signal Transduction in Receptor for Advanced Glycation End Products (RAGE) , 2011, The Journal of Biological Chemistry.

[29]  V. Torchilin,et al.  Cell-penetrating TAT peptide in drug delivery systems: Proteolytic stability requirements , 2011, Drug delivery.

[30]  T. van der Poll,et al.  The role of receptor for advanced glycation endproducts (RAGE) in infection , 2011, Critical Care.

[31]  Jong Ran Lee,et al.  Role of Two Adaptor Molecules SLP-76 and LAT in the PI3K Signaling Pathway in Activated T Cells , 2011, The Journal of Immunology.

[32]  J. Boyington,et al.  The 1.5 Å Crystal Structure of Human Receptor for Advanced Glycation Endproducts (RAGE) Ectodomains Reveals Unique Features Determining Ligand Binding* , 2010, The Journal of Biological Chemistry.

[33]  P. Papapanou,et al.  Receptor for advanced glycation endproducts mediates pro-atherogenic responses to periodontal infection in vascular endothelial cells. , 2010, Atherosclerosis.

[34]  M. Baumann.  Advanced glycation endproducts in sepsis and mechanical ventilation: extra or leading man? , 2009, Critical care.

[35]  V. D’Agati,et al.  Interaction of the RAGE Cytoplasmic Domain with Diaphanous-1 Is Required for Ligand-stimulated Cellular Migration through Activation of Rac1 and Cdc42* , 2008, Journal of Biological Chemistry.

[36]  G. Koretzky,et al.  Requirements of SLP76 tyrosines in ITAM and integrin receptor signaling and in platelet function in vivo , 2008, The Journal of experimental medicine.

[37]  P. Parsons,et al.  Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury , 2008, Thorax.

[38]  M. Büchler,et al.  sRAGE is elevated in septic patients and associated with patients outcome. , 2008, The Journal of surgical research.

[39]  G. Feuerstein.  Cardiac RAGE in sepsis: call TOLL free for anti-RAGE. , 2008, Circulation research.

[40]  A. Carter,et al.  Identification, classification, and expression of RAGE gene splice variants , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  T. Poll,et al.  Targeting RAGE in sepsis , 2008 .

[42]  S. Opal,et al.  Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection , 2007, Critical care.

[43]  S. Opal,et al.  Antibodies against RAGE in sepsis and inflammation: implications for therapy , 2007, Expert opinion on pharmacotherapy.

[44]  N. Zhong,et al.  Detection of Severe Acute Respiratory Syndrome Coronavirus in the Brain: Potential Role of the Chemokine Mig in Pathogenesis , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  J. Bowie,et al.  The Many Faces of SAM , 2005, Science's STKE.

[46]  Jun Xu,et al.  Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. , 2005, American journal of respiratory and critical care medicine.

[47]  U. Andersson,et al.  RAGE is the Major Receptor for the Proinflammatory Activity of HMGB1 in Rodent Macrophages , 2005, Scandinavian journal of immunology.

[48]  M. Nakajima,et al.  The receptor for advanced glycation end‐products (RAGE) directly binds to ERK by a D‐domain‐like docking site , 2003, FEBS letters.

[49]  Peter A. Ward,et al.  Novel strategies for the treatment of sepsis , 2003, Nature Medicine.

[50]  K. Tracey,et al.  HMGB1 as a late mediator of lethal systemic inflammation. , 2001, American journal of respiratory and critical care medicine.

[51]  L. Lue,et al.  Involvement of Microglial Receptor for Advanced Glycation Endproducts (RAGE) in Alzheimer's Disease: Identification of a Cellular Activation Mechanism , 2001, Experimental Neurology.

[52]  A. Schmidt,et al.  The biology of the receptor for advanced glycation end products and its ligands. , 2000, Biochimica et biophysica acta.

[53]  Peer Bork,et al.  SAM as a protein interaction domain involved in developmental regulation , 1997, Protein science : a publication of the Protein Society.

[54]  D. Christiani,et al.  Plasma sRAGE Acts as Genetically Regulated Causal Intermediate in Sepsis-Associated ARDS. , 2019, American journal of respiratory and critical care medicine.

[55]  M. Leone,et al.  Sam domains in multiple diseases. , 2018, Current medicinal chemistry.

[56]  J. Uribarri,et al.  Advanced Glycation End Products (AGE) and Diabetes: Cause, Effect, or Both? , 2013, Current Diabetes Reports.

[57]  Sreedhar Bodiga,et al.  Advanced glycation end products: role in pathology of diabetic cardiomyopathy , 2013, Heart Failure Reviews.

[58]  Zhong Tian.  Using FRET to Study The Interaction Domain of TLR4 Binding to MD-2 in Living Cells , 2009 .